Bronchospasmolytic effect of oxitropium bromide following powder inhalation in anaesthetized dogs.
A marked and long-lasting bronchospasmolytic effect without any cardiovascular side effects has been demonstrated in anaesthetized dogs following inhalation of 0.1 mg oxitropium bromide, with glucose as vehicle, administered as powder in powder inhaler capsules.
Traunecker
W
W
Department of Pharmacology, Boehringer Ingelheim KG, Ingelheim/Rheir, Fed. Rep. of Germany.
D000336:Aerosols; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001986:Bronchial Spasm / Q000517:prevention & control*; D004285:Dogs; D006339:Heart Rate / Q000187:drug effects; D009200:Myocardial Contraction / Q000187:drug effects; D010276:Parasympatholytics / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011208:Powders; D012602:Scopolamine Derivatives / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
D000336:Aerosols; D010276:Parasympatholytics; D011208:Powders; D012602:Scopolamine Derivatives; C017590:oxitropium